Detailed financial statements for Pluri Inc. (PLUR): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology.
Analysis Summary
Trailing-twelve-month margins: gross margin 19.0%, operating margin -24.1%, net margin -24.2%.
At the current price of $1.14, PLUR has negative trailing earnings (P/E not meaningful) and an ROE of 203.55%. Market capitalisation stands at $12M.
Balance sheet quality for PLUR: current ratio of 0.3, net debt of $27.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $50000 | $54000 | $23000 | 0 | $234000 | $287000 | $326000 | $1.3M | $1.0M |
| Cost of Revenue | $2.2M | $2000 | $2000 | $1.6M | $1.4M | $1.1M | $9000 | $4000 | $682000 | $563000 |
| Gross Profit | -$2.2M | $48000 | $52000 | -$1.5M | -$1.4M | -$819000 | $278000 | $322000 | $654000 | $453000 |
| Research & Development | $21.1M | $22.6M | $24.6M | $20.1M | $30.1M | $24.4M | $15.7M | $12.4M | $12.9M | $15.3M |
| Selling, General & Admin | $6.9M | $11.2M | $9.2M | $7.8M | $20.6M | $17.4M | $11.8M | $10.0M | $10.0M | $10.3M |
| Operating Expenses | $28.0M | $33.8M | $35.6M | $27.9M | $49.3M | $40.8M | $27.5M | $22.5M | $22.8M | $25.4M |
| Operating Income | -$28.0M | -$33.7M | -$35.5M | -$29.5M | -$50.6M | -$41.6M | -$27.2M | -$22.2M | -$22.2M | -$24.9M |
| EBITDA | -$25.6M | -$24.1M | -$33.3M | -$27.4M | -$48.4M | -$39.4M | -$27.7M | -$20.2M | -$22.1M | -$24.4M |
| Interest Expense | 0 | $937000 | $29000 | $196000 | $78000 | $887000 | $843000 | $866000 | $873000 | -$932000 |
| Pre-tax Income | -$27.8M | -$26.1M | -$35.3M | -$29.2M | -$49.9M | -$41.4M | -$28.9M | -$21.3M | -$23.3M | -$25.4M |
| Income Tax | -$205000 | 0 | -$94000 | 0 | 0 | 0 | 0 | 0 | -$5000 | -$25000 |
| Net Income | -$27.8M | -$26.1M | -$35.3M | -$29.2M | -$49.9M | -$41.2M | -$28.3M | -$20.9M | -$22.6M | -$23.8M |
| EPS | $-25.45 | $-19.74 | $-23.20 | $-12.80 | $-14.19 | $-10.24 | $-6.18 | $-3.99 | $-3.56 | $-2.44 |
| EPS (Diluted) | $-25.45 | $-19.74 | $-23.20 | $-12.80 | $-14.19 | $-10.24 | $-6.18 | $-3.99 | $-3.56 | $-2.44 |
| Shares Outstanding (Diluted) | $1.1M | $1.3M | $1.5M | $2.3M | $3.5M | $4.0M | $4.6M | $5.2M | $6.3M | $9.7M |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.7M | $8.8M | $4.1M | $8.8M | $31.2M | $9.8M | $5.4M | $6.8M | $5.9M | $3.5M |
| Short-term Investments | $21.4M | $21.1M | $19.6M | $37.5M | $33.7M | $45.2M | $34.8M | $23.2M | $14.7M | $4.3M |
| Receivables | $1.2M | $847000 | $1.4M | $1.6M | $1.5M | $1.3M | $527000 | $638000 | $722000 | $219000 |
| Inventory | 0 | 0 | $692000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $29.0M | $32.0M | $26.4M | $48.5M | $67.4M | $57.7M | $41.4M | $31.1M | $22.1M | $8.7M |
| Property, Plant & Equipment | $7.3M | $5.7M | $3.8M | $3.8M | $2.2M | $9.0M | $8.3M | $7.2M | $8.7M | $7.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.1M | $3.1M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.8M | $2.6M |
| Total Assets | $37.5M | $39.0M | $31.3M | $65.5M | $93.5M | $68.1M | $50.8M | $39.5M | $38.7M | $24.9M |
| Accounts Payable | $2.0M | $3.3M | $2.3M | $2.0M | $2.5M | $1.8M | $1.8M | $964000 | $866000 | $702000 |
| Short-term Debt | 0 | 0 | 0 | $1.0M | 0 | 0 | 0 | 0 | $27.3M | $27.4M |
| Total Current Liabilities | $5.4M | $8.5M | $8.2M | $8.0M | $11.5M | $6.8M | $5.6M | $4.5M | $32.3M | $32.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | $23.9M | $21.7M | $23.5M | $24.0M | 0 | 0 |
| Total Liabilities | $7.3M | $10.5M | $9.5M | $9.4M | $36.4M | $35.9M | $35.5M | $34.1M | $39.5M | $42.3M |
| Retained Earnings | -$189.6M | -$215.7M | -$251.0M | -$280.2M | -$330.0M | -$371.3M | -$399.6M | -$420.5M | -$443.1M | -$466.9M |
| Total Equity | $30.3M | $28.5M | $21.8M | $56.1M | $57.2M | $30.0M | $13.4M | $96000 | -$6.8M | -$23.0M |
| Total Debt | 0 | 0 | 0 | $1.6M | $24.6M | $28.8M | $29.9M | $29.6M | $34.0M | $34.9M |
| Net Debt | -$26.1M | -$29.9M | -$23.7M | -$44.8M | -$40.4M | -$26.2M | -$10.3M | -$373000 | $13.4M | $27.1M |
| Working Capital | $23.6M | $23.5M | $18.2M | $40.5M | $55.9M | $50.9M | $35.8M | $26.7M | -$10.2M | -$24.0M |
Cash Flow (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$27.8M | -$26.1M | -$35.3M | -$29.2M | -$49.9M | -$41.4M | -$28.9M | -$21.3M | -$23.2M | -$25.4M |
| Depreciation & Amortization | $2.2M | $2.0M | $2.0M | $1.6M | $1.4M | $1.1M | $362000 | $253000 | $316000 | $511000 |
| Stock-based Compensation | $3.7M | $6.5M | $5.1M | $2.6M | $14.0M | $8.9M | $4.0M | $2.6M | $2.1M | $3.7M |
| Change in Working Capital | -$134000 | $3.7M | -$1.3M | -$1.3M | $3.5M | -$5.1M | $1.7M | -$21000 | $4.2M | $1.6M |
| Operating Cash Flow | -$21.6M | -$21.4M | -$29.5M | -$26.4M | -$30.9M | -$36.5M | -$22.9M | -$18.0M | -$18.2M | -$19.6M |
| Capital Expenditure | -$378000 | -$342000 | -$239000 | -$270000 | -$373000 | -$280000 | -$262000 | -$323000 | -$1.6M | -$633000 |
| Acquisitions | $30000 | -$1.9M | $6000 | 0 | 0 | 0 | 0 | 0 | $373000 | $18000 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$22.0M | -$21.7M | -$29.7M | -$26.6M | -$31.3M | -$36.8M | -$23.1M | -$18.3M | -$19.8M | -$20.2M |
Growth & Margins (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +8.0% | -57.4% | -100.0% | +22.6% | +13.6% | +309.8% | -24.0% | |||
| Net Income Growth (YoY) | +6.1% | -35.1% | +17.4% | -71.1% | +17.3% | +31.3% | +26.2% | -8.1% | -5.5% | |
| EPS Growth (YoY) | +22.4% | -17.5% | +44.8% | -10.9% | +27.8% | +39.6% | +35.4% | +10.8% | +31.5% | |
| Shares Change (YoY) | +21.0% | +16.6% | +47.5% | +54.5% | +14.5% | +13.9% | +14.4% | +20.9% | +53.8% | |
| FCF Growth (YoY) | +1.2% | -36.7% | +10.3% | -17.4% | -17.6% | +37.1% | +20.7% | -8.1% | -2.0% | |
| Gross Margin | 96.0% | 96.3% | -6726.1% | -350.0% | 96.9% | 98.8% | 49.0% | 44.6% | ||
| Operating Margin | -67462.0% | -65800.0% | -128156.5% | -17774.8% | -9493.4% | -6796.9% | -1659.9% | -2454.5% | ||
| EBITDA Margin | -48216.0% | -61750.0% | -119069.6% | -16852.1% | -9645.3% | -6204.0% | -1651.6% | -2404.2% | ||
| Net Margin | -52252.0% | -65383.3% | -126747.8% | -17624.8% | -9867.9% | -6407.4% | -1690.3% | -2344.6% | ||
| FCF Margin | -43444.0% | -54985.2% | -115821.7% | -15718.4% | -8055.4% | -5627.0% | -1484.2% | -1990.3% | ||
| Effective Tax Rate | 0.7% | -0.0% | 0.3% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | 0.0% | 0.1% |
Per-Share Data (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-20.12 | $-16.42 | $-19.26 | $-11.71 | $-8.90 | $-9.14 | $-5.05 | $-3.50 | $-3.13 | $-2.08 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $1.1M | $1.3M | $1.5M | $2.3M | $3.5M | $4.0M | $4.6M | $5.2M | $6.3M | $9.7M |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | 203.55% |
| Return on Invested Capital | -117.79% |
| Return on Assets | -100.41% |
| Gross Margin | 19.00% |
| Operating Margin | -2412.14% |
| Net Margin | -2424.75% |
Financial Health
| Debt / Equity | -1.81 |
| Current Ratio | 0.33 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -17.73 |
Key Ratios (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -4.02 | -4.94 | -2.03 | -5.52 | -2.23 | -0.96 | -1.04 | -1.44 | -1.39 | -0.86 |
| P/B | 3.70 | 4.53 | 3.34 | 2.87 | 1.95 | 1.32 | 2.20 | 314.40 | -4.58 | -0.88 |
| P/S | 0.00 | 2582.50 | 1347.82 | 6995.13 | 0.00 | 169.21 | 102.18 | 92.58 | 23.48 | 20.04 |
| Gross Margin | 0.0% | 96.0% | 96.3% | -6726.1% | 0.0% | -350.0% | 96.9% | 98.8% | 49.0% | 44.6% |
| Operating Margin | 0.0% | -67462.0% | -65800.0% | -128156.5% | 0.0% | -17774.8% | -9493.4% | -6796.9% | -1659.9% | -2454.5% |
| Net Margin | 0.0% | -52252.0% | -65383.3% | -126747.8% | 0.0% | -17624.8% | -9867.9% | -6407.4% | -1690.3% | -2344.6% |
Related companies: ANTX · BOLD · IBIO · INTS · ITRM · JSPR · NXTC
Explore sector: Healthcare · Biotechnology
More sections of PLUR: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks